To verify the therapeutic potential of Baicalein, the inhibitory effects of IM and Baicalein, individual or combined, were compared against CML CD34+ cells in engrafted NOD/SCID mice (Fig. 7A). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.